Substrates | Metabolites | Inhibitors | Putative Enzyme(s) Involved | AUCR | ID Number | Additional Dataa | Objective Function | Reference (PubMed ID) | |
---|---|---|---|---|---|---|---|---|---|
Parent | Metabolite | ||||||||
Chlorpromazine | 7-Hydroxy chlorpromazine | Quinidine (166 mg) | CYP2D6, CYP3A | 1.40 | 1 | Table S7, Fig. S7 | AUCinf | AUCinf | 8739822 |
Desipramine | 2-Hydroxy desipramine | Fluoxetine (60 mg) | CYP2D6 | 2.58b | 2 | Table S8.1, Fig. S8.1 | AUCinf | Ae | 1544284 |
10.6c | 3 | Table S8.2, Fig. S8.2 | |||||||
Fentanyl | Norfentanyl | Fluconazole (200 mg) | CYP3A | 1.26 | 4 | Table S9.1, Fig. S9.1 | AUCinf | AUCinf | 17987285 |
Voriconazole (200 mg) | CYP3A | 1.39 | 5 | Table S9.2, Fig. S9.2 | |||||
Flurbiprofen | 4ʹ-Hydroxy flurbiprofen | Fluconazole (200 mg) | CYP2C9 | 1.75 | 6 | Fig. 2/Table S.10.1, Fig. S10.1 | AUC | AUC | 22943633 |
2.02 | 7 | Table S10.2, Fig. S10.2 | 23047652 | ||||||
Hydrocodone | Hydromorphone | Quinidine (83 mg) | CYP2D6 | 1.21 | 8 | Table S11, Fig. S11 | AUCinf | AUCinf | 7693389 |
Imipramine | 2-Hydroxy imipramine, desipramine | Fluoxetine (60 mg) | CYP2D6, CYP2C19, CYP3A | 2.08b | 9 | Table S12.1, Fig. S12.1 | AUCinf | AUCinf/Ae | 1544284 |
3.56c | 10 | Table S12.2, Fig. S12.2 | |||||||
Lansoprazole | 5-Hydroxy lansoprazole, lansoprazole sulfone | Fluvoxamine (25 mg) | CYP2C19 | 4.00d | 11 | Table S13.1, Fig. S13.1 | AUCinf | AUCinf | 15496639 |
2.50e | 12 | Table S13.2, Fig S13.2 | |||||||
Clarithromycin (400 mg) | CYP3A | 1.38d | 13 | Table S13.3, Fig. S13.3 | 15752376 | ||||
1.76e | 14 | Table S13.4, Fig. S13.4 | |||||||
1.81f | 15 | Table S13.5, Fig. S13.5 | |||||||
Losartan | EXP-3174 | Fluconazole (200 mg) | CYP2C9, CYP3A | 1.69 | 16 | Table S14.1, Fig. S14.1 | AUCinf | AUCinf | 9357393 |
1.27 | 17 | Table S14.2, Fig. S14.2 | 9551703 | ||||||
Omeprazole | 5-Hydroxy omeprazole, omeprazole sulfone | Fluvoxamine (25 mg) | CYP2C19 | 5.62d | 18 | Table S15.1, Fig. S15.1 | AUCinf | AUC/AUCinf | 15025747 |
2.38e | 19 | Table S15.2, Fig. S15.2 | |||||||
Oxycodone | Noroxycodone, oxymorphone | Quinidine (166 mg) | CYP2D6 | 1.13 | 20 | Table S16.1, Fig. S16.1 | AUCinf | AUC/AUCinf | 9871425 |
Voriconazole (200 mg) | CYP3A | 3.57 | 21 | Table S16.2, Fig. S16.2 | 18836708 | ||||
Itraconazole (200 mg) | CYP3A | 2.43 | 22 | Table S16.3, Fig. S16.3 | 20076952 | ||||
Paroxetine (20 mg) | CYP2D6 | 1.11 | 23 | Table S16.4, Fig. S16.4 | 20642550 | ||||
Ropivacaine | (S)-2ʹ,6ʹ-pipecoloxylidide | Itraconazole (200 mg) | CYP3A | 1.23 | 24 | Table S17, Fig. S17 | AUCinf | AUC | 11322176 |
AUC, area under the plasma concentration–time curve; AUCinf, AUC from time 0 to infinity.
↵a Tables and figures indicated with an S are found in the supplemental data.
↵b Fluoxetine single dose.
↵c Fluoxetine multiple dose.
↵d CYP2C19 extensive metabolizer (EM).
↵e CYP2C19 intermediate metabolizer (IM).
↵f CYP2C19 poor metabolizer (PM).